期刊
BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION
卷 17, 期 6, 页码 908-915出版社
ELSEVIER SCIENCE INC
DOI: 10.1016/j.bbmt.2010.09.018
关键词
CMML; Cytogenetics; Comorbidity; Hematopoietic cell transplantation
资金
- National Institutes of Health, Bethesda, MD [P01HL036111, P01CA018029, P30CA015704, HL088021]
Hematopoietic cell transplantation (HCT) offers potentially curative therapy for chronic myelomonocytic leukemia (CMML). We evaluated HCT outcomes in 85 patients with CMML, 1.0-69.1 (median 51.7) years of age, with follow-up extending to 19 years. CMML was considered de novo in 71 and secondary in 14 patients. Conditioning regimens were of various intensities. Thirty-eight patients had related (34 HLA identical), and 47 (39 HLA matched) unrelated donors. The source of stem cells was marrow in 32 and peripheral blood progenitor cells in 53 patients. Acute graft-versus-host disease (aGVHD) grades II-IV occurred in 72% and chronic GVHD (cGVHD) in 26% of patients. Relapse incidence was 27% at 10 years. Relapse correlated with increasing scores by the MD Anderson prognostic score (P = .01). The major causes of death were relapse and infections +/- GVHD. Progression-free survival (PFS) was 38% at 10 years. Mortality was negatively correlated with pre-HCT hennatocrit (P = .007), and increased with high-risk cytogenetics (P = .02), higher HCT Comorbidity Index (P = .0008), and increased age (P = .02). WHO classification did not statistically significantly affect outcome. Thus, a proportion of patients with CMML have lasting remissions following allogeneic HCT and appear to be cured of their disease. Biol Blood Marrow Transplant 17: 908-915 (2011) (C) 2011 American Society for Blood and Marrow Transplantation
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据